Home/Pipeline/PCX12

PCX12

Pancreatic Cancer

Pre-clinicalActive

Key Facts

Indication

Pancreatic Cancer

Phase

Pre-clinical

Status

Active

Company

TherapyX

About TherapyX

TherapyX is pioneering a novel drug delivery platform, EXStaM, designed to encapsulate and deliver large biologic molecules orally and via other routes while preserving their full biological activity. Its pipeline includes several preclinical and early-stage programs targeting pancreatic cancer, gonorrhea, and Familial Adenomatous Polyposis (FAP), with one program having received FDA Orphan Drug Designation. Founded in 2016 by academic scientists, the company is privately held, pre-revenue, and has secured non-dilutive funding from grants, including a recent $3 million NIH award.

View full company profile

Therapeutic Areas

Oncology Infectious Disease Inflammatory Disorders

Other Pancreatic Cancer Drugs

Drug	Company	Phase	Status
Ampligen® (rintatolimod)	AIM ImmunoTech	Early Access Program	Active - Approved in the Netherlands at Erasmus MC
HBM9027	Harbour BioMed	Phase 1	Active (Global)
Small-Molecule Therapeutic	AIkido Labs	Pre-clinical	Active
AHPBA IRE Registry	AngioDynamics	Post-Market Registry	Active
SIMBs + Immunotherapy	Advanced Microbubbles	Pre-clinical	Validated in preclinical studies
CLS-014	CLS Therapeutics	Pre-clinical	Lead candidate
SOMA Platform	Coherence Neuro	Pre-clinical	Pipeline expansion launched in 2024
NP-G2-044	Novita Pharmaceuticals	Phase 2a	Orphan Drug Designated (Jan 2026)
Pritumumab (PTB)	Nascent Biotech	Phase II (Planned)	Exploratory
Pancreatic Cancer Test	Mosaique Diagnostic	Development	Active
Iontophoretic System	Continuity Biosciences	Pre-clinical	Active
Lixumistat (IM156)	ImmunoMet Therapeutics	Phase 1b	Active